| SCHEDULE OF AMOUNTS RECEIVABLE AND PREPAID EXPENSES |
SCHEDULE
OF AMOUNTS RECEIVABLE AND PREPAID EXPENSES
| | |
2025 | | |
2024 | |
| | |
July
31, | |
| | |
2025 | | |
2024 | |
| | |
| | |
| |
| Directors and officers insurance | |
$ | 564,794 | | |
$ | 632,657 | |
| Prepaid expense (a) | |
| 1,394,439 | | |
| 1,322,122 | |
| Subscription receipt (b) | |
| - | | |
| 736,359 | |
| Other prepaids | |
| 101,062 | | |
| 100,627 | |
| Amounts receivable and
prepaid expenses | |
$ | 2,060,295 | | |
$ | 2,791,765 | |
| |
(a) |
Prepaid expenses as of July 31, 2025 include amounts paid to certain vendors in respect of the Company’s ongoing
pivotal phase III trial study. These amounts are amortized over the period of the clinical trial. Prepaid expenses estimated to be expensed
within 12 months amount to $1,394,439 in 2025 compared to 1,322,122 in 2024 and are included in current assets, whilst the balance, extending
longer than 12 months, amounts to $717,508 in 2025 as compared to 1,211,946 in 2024 and is included in non-current assets under long-term
prepaid expenses. |
| |
|
|
| |
(b) |
The
subscription receipt relates to the May 2024 Offering (see note 9(b)(ii)(1)). All the funds have been received during the year ended July 31, 2025. |
|